[ BCG-immunotherapy and bladder cancer].
Rischmann
Pascal
P
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000283:Administration, Intravesical; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015653:Cystectomy; D006801:Humans; D016685:Mitomycin / Q000008:administration & dosage / Q000627:therapeutic use; D015242:Ofloxacin / Q000008:administration & dosage / Q000627:therapeutic use; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*
D000276:Adjuvants, Immunologic; D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic; D001500:BCG Vaccine; D016685:Mitomycin; D015242:Ofloxacin